Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan
This study will determine if PRP treatment of FAI improves (i) patient reported outcome scores and (ii) hip functional stability compared to standard corticosteroid treatment and if PRP treatment of FAI reduces (i) radiographic and (ii) biochemical markers of joint inflammation and cartilage degradation.
Age
18–45
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with symptomatic FAI
Clinical and radiographic evidence of FAI
Patients able to provide consent to study participation
Completion of 6 weeks of physical therapy program
You may not be if
Established Osteoarthritis (Kellgren-Lawrence \> 3)
Minimum joint space \> 2 mm as measured on AP radiograph
Hip dysplasia (center edge angle \< 20° on AP radiograph)
Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes
Patients with ongoing infection including HIV and Hepatitis
Patient with history of osteomyelitis/septic arthritis
Anticoagulation therapy
Patients who are pregnant or breast feeding
Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis
Patients taking immunosuppressant medication
Patients with abnormal hematology or serum chemistry lab results
Patients receiving injection to treatment knee within 2 months of study enrollment
